Objective： To evaluate the effectiveness and safety of βelemene Injection as an adjunctive treatment for lung cancer by systematic review. Methods： We retrieved randomized controlled clinical trials related to the ...Objective： To evaluate the effectiveness and safety of βelemene Injection as an adjunctive treatment for lung cancer by systematic review. Methods： We retrieved randomized controlled clinical trials related to the use of β elemene Injection as an adjunctive treatment for lung cancer from Chinese Biomedical （CBMweb）, Chinese Medical Current Content （CMCC）, China National Knowledge Infrastructure （CNKI）, Chinalnfo, Cochrane Central Register of Controlled Trials; MEDLINE, EMBASE, OVID and TCMLARS. We also referred to an unpublished conference proceeding titled Clinical Use and Basic： Elemene Injection. We then divided the studies into nonsmall cell lung cancer （NSCLC） and small cell lung cancer （SCLC） subgroups by RevMan 5.1 software. Results： A total of 21 source documents （1,467 patients） matched prespecified criteria for determining the effectiveness and safety of β elemene Injection as an adjunctive treatment for lung cancer. Five studies involving 285 NSCLC patients reported a higher 24month survival rate （39.09%） with the adjunctive treatment than with chemotherapy alone （26.17%; RR, 1.51; 95% CI, 1.03 to 2.21）. Four studies involving 445 patients reported that the increased probability for improved performance status for patients treated with elemenebased combinations was higher than that of patients treated with chemotherapy alone （RR, 1.82; 95% CI, 1.45 to 2.29）. The results from a subgroup analysis on 12 studies involving 974 NSCLC patients and 9 studies involving 593 patients with both SCLC and NSCLC showed that the tumor control rate for NSCLC improved more in the elemenebased combinations treatment group （78.70%） than in the chemotherapy alone control group （71.31%; RR, 1.06; 95% CI, 1.00 to 1.12）. The tumor response rate for NSCLC also improved more among patients treated with elemene based combinations （50.71%） than among patients treated with chemotherapy alone （38.04%; RR, 1.34; 95%CI, 1.17 to 1.54）. In addition, the main adverse reaction to βelemene Injection was phlebitis, but usually only to a mild degree. An Egger＇s test showed no publication bias in our study （P=0.7030）. Conclusions： The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined with β elemene injection as an adjunctive treatment. The combined treatment can result in an improved quality of life and prolonged survival. However, these results require confirmation by rigorously controlled trials.展开更多
文摘Objective： To evaluate the effectiveness and safety of βelemene Injection as an adjunctive treatment for lung cancer by systematic review. Methods： We retrieved randomized controlled clinical trials related to the use of β elemene Injection as an adjunctive treatment for lung cancer from Chinese Biomedical （CBMweb）, Chinese Medical Current Content （CMCC）, China National Knowledge Infrastructure （CNKI）, Chinalnfo, Cochrane Central Register of Controlled Trials; MEDLINE, EMBASE, OVID and TCMLARS. We also referred to an unpublished conference proceeding titled Clinical Use and Basic： Elemene Injection. We then divided the studies into nonsmall cell lung cancer （NSCLC） and small cell lung cancer （SCLC） subgroups by RevMan 5.1 software. Results： A total of 21 source documents （1,467 patients） matched prespecified criteria for determining the effectiveness and safety of β elemene Injection as an adjunctive treatment for lung cancer. Five studies involving 285 NSCLC patients reported a higher 24month survival rate （39.09%） with the adjunctive treatment than with chemotherapy alone （26.17%; RR, 1.51; 95% CI, 1.03 to 2.21）. Four studies involving 445 patients reported that the increased probability for improved performance status for patients treated with elemenebased combinations was higher than that of patients treated with chemotherapy alone （RR, 1.82; 95% CI, 1.45 to 2.29）. The results from a subgroup analysis on 12 studies involving 974 NSCLC patients and 9 studies involving 593 patients with both SCLC and NSCLC showed that the tumor control rate for NSCLC improved more in the elemenebased combinations treatment group （78.70%） than in the chemotherapy alone control group （71.31%; RR, 1.06; 95% CI, 1.00 to 1.12）. The tumor response rate for NSCLC also improved more among patients treated with elemene based combinations （50.71%） than among patients treated with chemotherapy alone （38.04%; RR, 1.34; 95%CI, 1.17 to 1.54）. In addition, the main adverse reaction to βelemene Injection was phlebitis, but usually only to a mild degree. An Egger＇s test showed no publication bias in our study （P=0.7030）. Conclusions： The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined with β elemene injection as an adjunctive treatment. The combined treatment can result in an improved quality of life and prolonged survival. However, these results require confirmation by rigorously controlled trials.
